Colorectal cancer
Conditions
Interventions
Furquitinib group:Furquitinib
Sponsors
Maoming people's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male or female, older than 18 years; 2.PS 0-2; 3. Colorectal cancer confirmed by histology or cytology has received first-line and second-line chemotherapy, whether or not treatment with bevacizumab or cetuximab; 4. The life expectancy is more than 12 weeks; 5. Sign informed consent; 6. There are measurable tumor lesions in imaging; 7. Be able to comply with the research and follow-up procedures.
Exclusion criteria
Exclusion criteria: 1. Any unstable systemic disease (including active infection, poorly controlled hypertension, unstable angina, congestive heart failure, liver, kidney or metabolic disease); 2. Before treatment, he received regorafenib and furquintinib for systematic anti-tumor treatment; 3. Patients who are unable to accept oral administration, need intravenous high-energy nutrition, have undergone surgery affecting absorption before, or have active peptic ulcer; 4. Lactating women; 5. Granulocyte count is less than 1.5 * 10^9/L, platelet count is less than 75 * 10^9/L; 6. Serum bilirubin >1.5 ULN; 7. AST and ALT >2 ULN, and >5 ULN in case of liver metastasis; Serum creatinine >1.5 ULN, or creatinine clearance rate was less than 50 ml/min.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Countries
China
Contacts
Public ContactYisheng Huang
Maoming people's Hospital
Outcome results
None listed